Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. 10 stocks we like better than ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Anjalee Khemlani is an award-winning healthcare and business reporter at Yahoo Finance covering the entire healthcare sector, including pharma, health tech, providers, insurers, PBMs and health ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...